BACKGROUND: The aim of this study was to determine outcomes in patients with breast cancer treated with neoadjuvant chemotherapy. METHODS: Seventy-two consecutive patients receiving neoadjuvant chemotherapy for breast cancer were enrolled. RESULTS: Mastectomy was avoided in 46% of patients, and 42% converted to negative nodes after neoadjuvant chemotherapy. Thirteen patients (18%) achieved a pathologic complete response, which was associated with the estrogen receptor (ER)-negative/human epidermal growth factor receptor 2 (Her2)-negative subtype (58%) and was significantly less likely to occur in the ER+/Her2- subtype (2%) (P < .01). Patients with the ER+/Her2+ subtype were most likely to have no response or progression during chemotherapy, compared with those with the ER-/Her2- subtype (50% vs 0%, P = .01). Five-year survival for patients achieving a pathologic complete response was 100%, compared with 74% in the group with partial response and 48% in the group with no response or progression (P = .01). CONCLUSIONS: Neoadjuvant chemotherapy for patients with advanced breast cancer provided prognostic information, allowed evaluation of response to chemotherapy, decreased the mastectomy rate, and potentially reduced the need for axillary lymph node dissection.
BACKGROUND: The aim of this study was to determine outcomes in patients with breast cancer treated with neoadjuvant chemotherapy. METHODS: Seventy-two consecutive patients receiving neoadjuvant chemotherapy for breast cancer were enrolled. RESULTS: Mastectomy was avoided in 46% of patients, and 42% converted to negative nodes after neoadjuvant chemotherapy. Thirteen patients (18%) achieved a pathologic complete response, which was associated with the estrogen receptor (ER)-negative/humanepidermal growth factor receptor 2 (Her2)-negative subtype (58%) and was significantly less likely to occur in the ER+/Her2- subtype (2%) (P < .01). Patients with the ER+/Her2+ subtype were most likely to have no response or progression during chemotherapy, compared with those with the ER-/Her2- subtype (50% vs 0%, P = .01). Five-year survival for patients achieving a pathologic complete response was 100%, compared with 74% in the group with partial response and 48% in the group with no response or progression (P = .01). CONCLUSIONS: Neoadjuvant chemotherapy for patients with advanced breast cancer provided prognostic information, allowed evaluation of response to chemotherapy, decreased the mastectomy rate, and potentially reduced the need for axillary lymph node dissection.
Authors: Roman Rouzier; Charles M Perou; W Fraser Symmans; Nuhad Ibrahim; Massimo Cristofanilli; Keith Anderson; Kenneth R Hess; James Stec; Mark Ayers; Peter Wagner; Paolo Morandi; Chang Fan; Islam Rabiul; Jeffrey S Ross; Gabriel N Hortobagyi; Lajos Pusztai Journal: Clin Cancer Res Date: 2005-08-15 Impact factor: 12.531
Authors: J D Cunningham; S E Weiss; S Ahmed; J M Bratton; I J Bleiweiss; P I Tartter; S T Brower Journal: Cancer Invest Date: 1998 Impact factor: 2.176
Authors: T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: Aman U Buzdar; Nuhad K Ibrahim; Deborah Francis; Daniel J Booser; Eva S Thomas; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Banu K Arun; Sharon H Giordano; Massimo Cristofanilli; Debra K Frye; Terry L Smith; Kelly K Hunt; Sonja E Singletary; Aysegul A Sahin; Michael S Ewer; Thomas A Buchholz; Donald Berry; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2005-02-28 Impact factor: 44.544
Authors: G Bonadonna; P Valagussa; C Brambilla; L Ferrari; A Moliterni; M Terenziani; M Zambetti Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Allen M Chen; Funda Meric-Bernstam; Kelly K Hunt; Howard D Thames; Mary Jane Oswald; Elesyia D Outlaw; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Merrick I Ross; S Eva Singletary; Fredrick C Ames; Barry W Feig; Aysegul A Sahin; George H Perkins; Naomi R Schechter; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: T J Powles; T F Hickish; A Makris; S E Ashley; M E O'Brien; V A Tidy; S Casey; A G Nash; N Sacks; D Cosgrove Journal: J Clin Oncol Date: 1995-03 Impact factor: 44.544
Authors: William G Cance; Lisa A Carey; Benjamin F Calvo; Carolyn Sartor; Lynda Sawyer; Dominic T Moore; Julian Rosenman; David W Ollila; Mark Graham Journal: Ann Surg Date: 2002-09 Impact factor: 12.969
Authors: Philip M Spanheimer; Allison W Lorenzen; James P De Andrade; Mikhail V Kulak; Jennifer C Carr; George W Woodfield; Sonia L Sugg; Ronald J Weigel Journal: Ann Surg Oncol Date: 2015-05-14 Impact factor: 5.344
Authors: Nataliya Babyshkina; Elena Malinovskaya; Stanislav Patalyak; Olga Bragina; Natalia Tarabanovskaya; Artem Doroshenko; Elena Slonimskaya; Vladimir Perelmuter; Nadejda Cherdyntseva Journal: Med Oncol Date: 2014-08-20 Impact factor: 3.064
Authors: Maria V Bogachek; Jung Min Park; James P De Andrade; Mikhail V Kulak; Jeffrey R White; Tong Wu; Philip M Spanheimer; Thomas B Bair; Alicia K Olivier; Ronald J Weigel Journal: Ann Surg Oncol Date: 2014-10-18 Impact factor: 5.344
Authors: Kandace P McGuire; E Shelley Hwang; Alan Cantor; Mehra Golshan; Funda Meric-Bernstam; Janet K Horton; Rita Nanda; Keith D Amos; Andres Forero; Cliff A Hudis; Ingrid Meszoely; Jennifer F De Los Santos Journal: Ann Surg Oncol Date: 2014-07-25 Impact factor: 5.344
Authors: Philip M Spanheimer; Jung-Min Park; Ryan W Askeland; Mikhail V Kulak; George W Woodfield; James P De Andrade; Anthony R Cyr; Sonia L Sugg; Alexandra Thomas; Ronald J Weigel Journal: Clin Cancer Res Date: 2014-02-13 Impact factor: 12.531
Authors: Philip M Spanheimer; Anthony R Cyr; Matthew P Gillum; George W Woodfield; Ryan W Askeland; Ronald J Weigel Journal: Ann Surg Date: 2014-04 Impact factor: 12.969